HomeProductsBioactive CompoundsMetabolic EnzymesCathepsinOdanacatib
Chemical structure of CAS 603139-19-1

Odanacatib

CAS No.603139-19-1
MDL No.MFCD11042419
MFC25H27F4N3O3S
MW525.60
InChI KeyFWIVDMJALNEADT-SFTDATJTSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.603139-19-1
Product NameOdanacatib

Biological Targets

CTSK

Associated Conditions

postmenopausal osteoporosis·osteoarthritis·prostate cancer·breast cancer·osteoporosis·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 44, Issue 9 • 2016
PMID: 27402726DOI: 10.1124/dmd.116.069906

Merck &Co. drops osteoporosis drug odanacatib.

Nature reviews. Drug discovery • Vol. 15, Issue 10 • 2016
PMID: 27681784DOI: 10.1038/nrd.2016.207

Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 42, Issue 5 • 2014
PMID: 24553380DOI: 10.1124/dmd.113.056580

Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.

The Journal of clinical endocrinology and metabolism • Vol. 99, Issue 2 • 2014
PMID: 24276460DOI: 10.1210/jc.2013-1688

Documentation

Similar Products